✉  info@marketresearchfuture.com   đź“ž  +1 (855) 661-4441(US)   đź“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Global Dry Age-Related Macular Degeneration Market Research Report Information By Stages (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, and Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, and Above 40 Years), By Diagnosis and Treatment (Treatment and Diagnosis), By Route of Administration (Oral and Injectables), By End Users (Hospitals & Clinics, Diagnostic Centers, and Academic & Research Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest O


ID: MRFR/HC/9174-CR | 171 Pages | Author: Kinjoll Dey| August 2021

Research Methodology on Dry Age-Related Macular Degeneration AMD Market


Introduction


Dry Age-Related Macular Degeneration (AMD) is one of the leading causes of severe vision loss and blindness among seniors in developed countries. Market Research Future (MRFR) estimates that the Dry AMD market will grow at a rapid pace by the year 2030. This research report examines the factors impacting the increasing prevalence of AMD and provides a comprehensive assessment of the Dry AMD market.


The primary objectives of this research report are to assess the current and historical status of the Dry AMD market, create a current market projection of Dry AMD for the forecast period 2023 to 2030, identify the current and potential drivers of growth for the Dry AMD market, and explore the potential market opportunities for manufacturers of treatments for Dry AMD.


Research Objectives


The primary objective of this research is to determine the current and historical status of the Dry AMD market. The secondary research objective of this study is to create a market projection for the Dry AMD market. 


Research Methodology


The overall research methodology employed in this report involves both primary and secondary research. The primary research component consists of interviews with industry experts as well as surveys of patients, doctors, and manufacturers of Dry AMD treatments. The secondary research component involves using a wide variety of sources, including published materials, medical journals, and reports from patient advocacy groups.


Definition of the Population


The population of the Dry AMD market includes all people who have been diagnosed with Dry AMD and who are currently in the treatment market. The population of this report also includes all medical professionals and companies manufacturing/distributing treatments for Dry AMD.


Sampling and Data Collection


To collect data for this report, a multilayered sampling process is employed. For primary data collection, a convenience sample of patients with Dry AMD is used, whereby patients are asked to participate in one-on-one interviews. Patients are also asked to complete an online survey to provide further insight into their experiences with Dry AMD. For secondary data collection, an exhaustive review of medical journals, patient advocacy reports, and other published materials is conducted.


Outcomes and Data Analysis


The data collected from both primary and secondary sources is then analyzed for patterns and trends. The data is grouped by region, market size, treatment type, and current and potential market drivers. An analysis of the data is then conducted to determine the overall current and projected market size for Dry AMD treatments. The analysis is then used to form the basis of the conclusions of this report.


Conclusion


This research report provides a comprehensive assessment of the current and projected Dry AMD market. By utilizing a multi-layered sampling and data collection process, the current and potential drivers of the Dry AMD market are identified. The data collected is then analyzed to determine the overall market size for Dry AMD treatments for the period 2023 to 2030.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 MARKET STRUCTURE

2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DRY AGE-RELATED MACULAR DEGENERATION

4.2.2 INCREASING HEALTHCARE EXPENDITURE

4.3 RESTRAINTS

4.3.1 FAILED CLINICAL TRAILS FOR DRY AMD

4.4 OPPORTUNITIES

4.4.1 INCREASE IN PIPELINE DRUGS FOR DRY AMD

4.4.2 DEVELOPMENT OF NEW TECHNOLOGIES FOR TREATMENT

4.5 EPIDEMIOLOGY OF DRY AMD

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE DRY AMD MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON PATIENTS WITH DRY AMD

5.3.3 IMPACT ON CLINICAL TRIALS

5.3.4 IMPACT ON R&D

5.3.5 IMPACT ON MARKET GROWTH

6 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES

6.1 OVERVIEW

6.2 EARLY AGE-RELATED MACULAR DEGENERATION

6.3 INTERMEDIATE AGE-RELATED MACULAR DEGENERATION

6.4 LATE AGE-RELATED MACULAR DEGENERATION

7 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP

7.1 OVERVIEW

7.2 ABOVE 40 YEARS

7.3 ABOVE 60 YEARS

7.4 ABOVE 75 YEARS

8 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT

8.1 OVERVIEW

8.2 TREATMENT

8.3 DIAGNOSIS

9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 ORAL

9.3 INJECTABLES

10 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL & CLINICS

10.3 DIAGNOSTIC CENTERS

10.4 ACADEMIC RESEARCH INSTITUTES

10.5 OTHERS

11 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 US

11.2.2 CANADA

11.3 EUROPE

11.3.1 GERMANY

11.3.2 UK

11.3.3 FRANCE

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 SOUTH KOREA

11.4.5 AUSTRALIA

11.4.6 REST OF ASIA-PACIFIC

11.5 REST OF THE WORLD

11.5.1 MIDDLE EAST

11.5.2 AFRICA

11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 COMPETITIVEOVERVIEW

12.2 MARKET SHARE ANALYSIS

12.3 MAJOR GROWTH STRATEGIES IN THE GLOBAL DRY AMD MARKET

12.4 COMPETITIVE BENCHMARKING

12.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DRY AMD MARKET

12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.6.1 CONTRACTS & AGREEMENTS

12.6.2 NEW PRODUCT DEVELOPMENTS/LAUNCHES

12.6.3 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES

12.6.4 INVESTMENT

12.7 MAJOR PLAYERS FINANCIAL MATRIX

12.7.1 SALES, 2020

12.7.2 R&D EXPENDITURE, 2020

13 COMPANY PROFILES

13.1 SANTEN PHARMACEUTICALS INC.

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 PRODUCTS/SERVICES OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 ALLERGAN PLC

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 PRODUCTS/SERVICES OFFERED

13.2.4 ALLERGAN: KEY DEVELOPMENTS

13.2.5 SWOT ANALYSIS

13.2.6 KEY STRATEGIES

13.3 BAUSCH HEALTH (VALEANT PHARMACEUTICALS)

13.3.1 COMPANY OVERVIEW

13.3.2 FINANCIAL OVERVIEW

13.3.3 PRODUCTS/SERVICES OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 SWOT ANALYSIS

13.3.6 KEY STRATEGIES

13.4 ALIMERA SCIENCES INC.

13.4.1 COMPANY OVERVIEWS

13.4.2 FINANCIAL OVERVIEW

13.4.3 PRODUCTS/SERVICES OFFERED

13.4.4 KEY DEVELOPMENTS

13.4.5 SWOT ANALYSIS

13.4.6 KEY STRATEGIES

13.5 RXI PHARMACEUTICALS, INC. (PHIO PHARMACEUTICALS CORP)

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 PRODUCTS/SERVICES OFFERED

13.5.4 KEY DEVELOPMENTS

13.5.5 SWOT ANALYSIS

13.5.6 KEY STRATEGIES

13.6 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD

13.6.1 COMPANY OVERVIEWS

13.6.2 FINANCIAL OVERVIEW

13.6.3 PRODUCTS/SERVICES OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 SWOT ANALYSIS

13.6.6 KEY STRATEGIES

13.7 BELITE BIO INC.

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 PRODUCTS/SERVICES OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 SWOT ANALYSIS

13.7.6 KEY STRATEGIES

13.8 KUBOTA VISION INC.

13.8.1 COMPANY OVERVIEW

13.8.2 FINANCIAL OVERVIEW

13.8.3 PRODUCTS/SERVICES OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 SWOT ANALYSIS

13.8.6 KEY STRATEGIES

13.9 IVERIC BIO

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 PRODUCTS/SERVICES OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 SWOT ANALYSIS

13.9.6 KEY STRATEGIES

13.10 EYESTEM RESEARCH PVT LTD

13.10.1 COMPANY OVERVIEW

13.10.2 FINANCIAL OVERVIEW

13.10.3 PRODUCTS/SERVICES OFFERED

13.10.4 KEY DEVELOPMENTS

13.10.5 SWOT ANALYSIS

13.10.6 KEY STRATEGIES

13.11 YUYANG DNU CO., LTD

13.11.1 COMPANY OVERVIEW

13.11.2 FINANCIAL OVERVIEW

13.11.3 PRODUCTS/SERVICES OFFERED

13.11.4 KEY DEVELOPMENTS

13.11.5 SWOT ANALYSIS

13.11.6 KEY STRATEGIES

13.12 STEALTH BIOTHERAPEUTICS CORP

13.12.1 COMPANY OVERVIEW

13.12.2 FINANCIAL OVERVIEW

13.12.3 PRODUCTS/SERVICES OFFERED

13.12.4 KEY DEVELOPMENTS

13.12.5 SWOT ANALYSIS

13.12.6 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES

14.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 DRY AMD DRUGS ONGOING CLINICAL TRIALS

TABLE 4 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 5 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR EARLY AMD, BY REGION, 2022-2030 (USD MILLION)

TABLE 6 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR INTERMEDIATE AMD, BY REGION, 2022-2030 (USD MILLION)

TABLE 7 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR LATE AMD, BY REGION, 2022-2030 (USD MILLION)

TABLE 8 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 9 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ABOVE 40 YEARS, BY REGION, 2022-2030 (USD MILLION)

TABLE 10 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ABOVE 60 YEARS, BY REGION, 2022-2030 (USD MILLION)

TABLE 11 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ABOVE 75 YEARS, BY REGION, 2022-2030 (USD MILLION)

TABLE 12 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION AMD MARKET, BY DIAGNOSIS AND TREATMENT, 2022-2030 (USD MILLION)

TABLE 13 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY REGION, 2022-2030 (USD MILLION)

TABLE 14 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 15 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 16 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITIONAL THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 17 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY REGION, 2022-2030 (USD MILLION)

TABLE 18 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 19 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 20 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ORAL, BY REGION, 2022-2030 (USD MILLION)

TABLE 21 ONGOING CLINICAL TRIALS RELATED TO AGE-RELATED MACULAR DEGENERATION, BY ROUTE OF ADMINISTRATION, 2020

TABLE 22 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR INJECTABLES, BY REGION, 2022-2030 (USD MILLION)

TABLE 23 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 24 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR HOSPITAL & CLINICS, BY REGION, 2022-2030 (USD MILLION)

TABLE 25 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2030 (USD MILLION)

TABLE 26 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2022-2030 (USD MILLION)

TABLE 27 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION)

TABLE 28 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2022-2030 ((USD MILLION)

TABLE 29 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 30 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 31 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 32 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 33 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 34 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR NUTRITION THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 35 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 36 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 37 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 38 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 39 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 40 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 41 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 42 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 43 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 44 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 45 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 46 US: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 47 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 48 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 49 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 50 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 51 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 52 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 53 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 54 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 55 CANADA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 56 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2022-2030 (USD MILLION)

TABLE 57 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 58 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 59 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 60 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 61 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 62 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 63 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 64 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 65 EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 66 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 67 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 68 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 69 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 70 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 71 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 72 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 73 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 74 GERMANY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 75 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 76 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 77 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 78 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 79 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 80 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 81 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 82 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 83 UK: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 84 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 85 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 86 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 87 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 88 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 89 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 90 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 91 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 92 FRANCE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 93 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 94 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 95 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 96 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 97 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 98 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 99 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 100 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 101 ITALY: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 102 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 103 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 104 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 105 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 106 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 107 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 108 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 109 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 110 SPAIN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 111 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 112 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 113 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 114 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 115 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 116 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 117 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 118 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 119 REST OF EUROPE: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 120 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY COUNTRY, 2022-2030 (USD MILLION)

TABLE 121 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 122 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 123 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 124 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 125 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 126 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 127 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 128 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 129 ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 130 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 131 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 132 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 133 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 134 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 135 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 136 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 137 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 138 CHINA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 139 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 140 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 141 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 142 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 143 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 144 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 145 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 146 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 147 JAPAN: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 148 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 149 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 150 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 151 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 152 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 153 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 154 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 155 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 156 INDIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 157 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 158 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 159 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 160 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 161 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 162 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 163 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 164 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 165 SOUTH KOREA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 166 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 167 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 168 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 169 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 170 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 171 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 172 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 173 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 174 AUSTRALIA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 175 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 176 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 177 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 178 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR TREATMENT, BY TYPE, 2022-2030 (USD MILLION)

TABLE 179 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR NUTRITION THERAPY, BY TYPE, 2022-2030 (USD MILLION)

TABLE 180 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR ANTIOXIDANTS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 181 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET FOR DIAGNOSIS, BY TYPE, 2022-2030 (USD MILLION)

TABLE 182 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 183 REST OF ASIA-PACIFIC: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 184 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION, 2022-2030 (USD MILLION)

TABLE 185 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 186 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 187 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 188 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 189 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 190 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR NUTRITION THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 191 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 192 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 193 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 194 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 195 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 196 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 197 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 198 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 199 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 200 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 201 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 202 MIDDLE EAST: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 203 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 204 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 205 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 206 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 207 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 208 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 209 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 210 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 211 AFRICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 212 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

TABLE 213 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

TABLE 214 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT & DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 215 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY TREATMENT TYPE, 2022-2030 (USD MILLION)

TABLE 216 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR TREATMENT TYPE, BY NUTRITION THERAPY, 2022-2030 (USD MILLION)

TABLE 217 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, FOR A NUTRITION THERAPY, BY ANTIOXIDANTS, 2022-2030 (USD MILLION)

TABLE 218 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION)

TABLE 219 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

TABLE 220 LATIN AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

TABLE 221 THE MOST ACTIVE PLAYERS IN THE GLOBAL DRY AMD MARKET

TABLE 222 CONTRACTS & AGREEMENTS

TABLE 223 NEW PRODUCT DEVELOPMENTS/LAUNCHES

TABLE 224 COLLABORATIONS/EXPANSIONS/PARTNERSHIPS/JOINT VENTURES

TABLE 225 INVESTMENT

TABLE 226 SANTEN PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED

TABLE 227 SANTEN PHARMACEUTICALS INC.: KEY DEVELOPMENTS

TABLE 228 ALLERGAN: PRODUCTS/SERVICES OFFERED

TABLE 229 BAUSCH HEALTH: PRODUCTS/SERVICES OFFERED

TABLE 230 BAUSCH HEALTH: KEY DEVELOPMENTS

TABLE 231 ALIMERA SCIENCES: PRODUCTS/SERVICES OFFERED

TABLE 232 RXI PHARMACEUTICALS, INC.: PRODUCTS/SERVICES OFFERED

TABLE 233 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: PRODUCTS/SERVICES OFFERED

TABLE 234 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: KEY DEVELOPMENTS

TABLE 235 BELITE BIO INC.: PRODUCTS/SERVICES OFFERED

TABLE 236 BELITE BIO INC.: KEY DEVELOPMENTS

TABLE 237 KUBOTA VISION INC.: PRODUCTS/SERVICES OFFERED

TABLE 238 IVERIC BIO: PRODUCTS/SERVICES OFFERED

TABLE 239 IVERIC BIO: KEY DEVELOPMENTS

TABLE 240 EYESTEM RESEARCH PVT LTD: PRODUCTS/SERVICES OFFERED

TABLE 241 YUYANG DNU CO., LTD: PRODUCTS/SERVICES OFFERED

TABLE 242 STEALTH BIOTHERAPEUTICS CORP: PRODUCTS/SERVICES OFFERED

TABLE 243 STEALTH BIOTHERAPEUTICS CORP: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL DRY AMD MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: DRY AGE-RELATED MACULAR DEGENERATION MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: DRY AMD MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: DRY AMD MARKET

FIGURE 9 GLOBAL DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY STAGES, 2022-2030 (USD MILLION)

FIGURE 10 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY AGE GROUP, 2022-2030 (USD MILLION)

FIGURE 11 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY DIAGNOSIS AND TREATMENT, 2022-2030 (USD MILLION)

FIGURE 12 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)

FIGURE 13 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY END USER, 2022-2030 (USD MILLION)

FIGURE 14 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET, BY REGION 2022-2030 (USD MILLION)

FIGURE 15 GLOBAL: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY REGION, 2020

FIGURE 16 NORTH AMERICA: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 17 EUROPE DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 18 ASIA-PACIFIC DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY COUNTRY, 2020

FIGURE 19 REST OF THE WORLD: DRY AGE-RELATED MACULAR DEGENERATION MARKET SHARE (%), BY REGION, 2020

FIGURE 20 MAJOR MANUFACTURERS MARKET SHARE ANALYSIS (%), 2020

FIGURE 21 CONTRACTS & AGREEMENTS: THE MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL DRY AMD MARKET

FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 23 SALES, 2020

FIGURE 24 MAJOR PLAYERS R&D EXPENDITURE, 2020

FIGURE 25 SANTEN PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 SANTEN PHARMACEUTICALS INC.: SWOT ANALYSIS

FIGURE 27 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 ALLERGAN: SWOT ANALYSIS

FIGURE 29 BAUSCH HEALTH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 BAUSCH HEALTH: SWOT ANALYSIS

FIGURE 31 ALIMERA SCIENCES: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 ALIMERA SCIENCES: KEY DEVELOPMENTS

FIGURE 33 ALIMERA SCIENCES: SWOT ANALYSIS

FIGURE 34 RXI PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 RXI PHARMACEUTICALS, INC.: SWOT ANALYSIS

FIGURE 36 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 OCUMENSION THERAPEUTICS (SHANGHAI) CO., LTD: SWOT ANALYSIS

FIGURE 38 BELITE BIO INC.: SWOT ANALYSIS

FIGURE 39 KUBOTA VISION INC.: FINANCIAL OVERVIEW

FIGURE 40 KUBOTA VISION INC.: SWOT ANALYSIS

FIGURE 41 IVERIC BIO.: SWOT ANALYSIS

FIGURE 42 EYESTEM RESEARCH PVT Ltd: SWOT ANALYSIS

FIGURE 43 YUYANG DNU CO., LTD: SWOT ANALYSIS

FIGURE 44 STEALTH BIOTHERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 45 STEALTH BIOTHERAPEUTICS CORP: SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Related Reports
report-img
US Dry Age-Related Macular Degeneration AMD Market
Press Release
Category icon
(AMD) are expected to boost the growth of the global dry age-related macular degeneration (AMD) m...
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
đź“ž  +1 (855) 661-4441(US)
đź“ž  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)